Marianne Ellen Pavel

Medizinische Fakultät Department of Medicine 1 – Gastroenterology, Pneumology and Endocrinology Professur für Endokrinologie

Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors (2019) Pavel ME, Phan AT, Wolin EM, Mirakhur B, Liyanage N, Pitman Lowenthal S, Fisher GA, Vinik AI Journal article Genomic profiling of NETs: a comprehensive analysis of the RADIANT trials (2019) Yao J, Garg A, Chen D, Capdevila J, Engstrom P, Pommier R, Van Cutsem E, et al. Journal article Long-term control with chemoradiation of initially metastatic mixed adenoneuroendocrine carcinoma of the rectum: A case report (2019) Semrau S, Agaimy A, Pavel ME, Lubgan D, Schmidt D, Golcher H, Grützmann R, et al. Journal article Long-Term Follow Up of Patients With Carcinoid Syndrome Diarrhea Treated With Telotristat Ethyl: A Pooled Analysis of Phase 2 and 3 Trials (2019) Anthony L, Kulke M, Caplin M, Bergsland E, Oberg K, Pavel ME, Horsch D, et al. Conference contribution Octreotide SC depot in patients with acromegaly and functioning neuroendocrine tumors: a phase 2, multicenter study (2019) Pavel ME, Borson-Chazot F, Cailleux A, Hoersch D, Lahner H, Pivonello R, Tauchmanova L, et al. Journal article Tumor growth rate as a metric of progression, response, and prognosis in pancreatic and intestinal neuroendocrine tumors (2019) Dromain C, Pavel ME, Ruszniewski P, Langley A, Massien C, Baudin E, Caplin ME Journal article The relevance of cancer related fatigue in neuroendocrine neoplasia patients (2019) Banz S, Mellar K, Letsch A, Scheibenbogen C, Pavel ME, Grabowski P Conference contribution Relationship Between Metabolic Toxicity and Efficacy of Everolimus in Patients With Neuroendocrine Tumors (NETs): A Pooled Analysis From the Randomized, Phase 3 RADIANT-3, and RADIANT-4 Trials (2019) Fazio N, Carnaghi C, Valle JW, Herbst F, Ridolfi A, Strosberg J, Kulke MH, et al. Conference contribution Systemic Markers of Inflammation in Neuroendocrine Tumors (NETs) and Outcomes With Everolimus: A Pooled Analysis From the Randomized, Phase 3 RADIANT-3, and RADIANT-4 Trials (2019) Chan DL, Yao JC, Camaghi C, Herbst F, Ridolfi A, Strosberg J, Kulke MH, et al. Conference contribution Systemic Anti-Cancer Therapies Impair the Nutritional Status of Neuroendocrine Tumor Patients (2019) Pevny S, Maasberg S, Karber M, Knappe-Drzikova B, Weylandt KH, Jann H, Pavel ME, et al. Conference contribution